PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

Figures & data

Table 1. Clinicopathological characteristics of patients and tumors (N = 758).

Characteristics		N (%)
Median age	Years (range)	62 (10–92.12)
Sex	Female	242 (49%)
	Male	250 (51%)
Tumor site	Extremities	208 (42%)
	Head and neck	9 (2%)
	Internal trunk	195 (39%)
	Superficial trunk	84 (17%)
Pathological type	Leiomyosarcoma	126 (27%)
	Liposarcoma	116 (25%)
	Undifferentiated sarcoma	162 (34%)
	Myxofibrosarcoma	34 (7%)
	Others	32 (7%)
Depth	Deep	144 (89%)
	Superficial	17 (11%)
Pathological grade	1	9 (4%)
	2	79 (32%)
	3	159 (64%)
Median pathological size	cm (range)	10 (1.2–39.5)
Pathological size	pT1	29 (17%)
	pT2	141 (83%)
Genetic profile	Simple	183 (25%)
	Complex	563 (75%)
CINSARC class	Good	418 (55%)
	Poor	340 (45%)

Figure 1. Metastasis-free survival according to PDL1 expression in soft-tissue sarcomas. (A) Kaplan–Meier MFS curves in all patients (N = 470). (B) Similar to (A), but in the learning set (N = 235) and according to PDL1 expression. (C) Similar to (B), but in the validation set (N = 235). (D) Similar to (B), but in the pooled learning and validation sets (N = 470).

Table 2. Correlations of PDL1 expression with clinicopathological variables (N = 758).

			PDL1 class
Characteristics		N	Low	High	p-value
Median age	Years (range)	492	62.13 (10–92.12)	62 (21–90)	0.17
Sex					0.46
	Female	242	150 (62%)	92 (38%)
	Male	250	146 (58%)	104 (42%)
Tumor site					0.6
	Extremities	208	115 (55%)	93 (45%)
	Head and neck	9	4 (44%)	5 (56%)
	Internal trunk	195	118 (61%)	77 (39%)
	Superficial trunk	84	47 (56%)	37 (44%)
Pathological type					2.84E−04
	Leiomyosarcoma	126	53 (42%)	73 (58%)
	Liposarcoma	116	79 (68%)	37 (32%)
	Undifferentiated sarcoma	162	100 (62%)	62 (38%)
	Myxofibrosarcoma	34	20 (59%)	14 (41%)
	Others	32	23 (72%)	9 (28%)
Depth					0.61
	Deep	144	86 (60%)	58 (40%)
	Superficial	17	9 (53%)	8 (47%)
Pathological grade					0.22
	1	9	6 (67%)	3 (33%)
	2	79	35 (44%)	44 (56%)
	3	159	87 (55%)	72 (45%)
Median pathological size	cm (range)	170	11.75 (58%)	8.4 (42%)	8.84E−03
Pathological size					0.84
	pT1	29	16 (55%)	13 (45%)
	pT2	141	82 (58%)	59 (42%)
Genetic profile					1.82E−04
	Simple	183	131 (72%)	52 (28%)
	Complex	563	315 (56%)	248 (44%)
CINSARC class					0
	Good	418	277 (66%)	141 (34%)
	Poor	340	179 (53%)	161 (47%)

Table 3. Univariate and multivariate prognostic analyses for metastasis-free survival (N = 470).

		Univariate			Multivariate
Characteristics		N	HR [95% CI]	p value	N	HR [95% CI]	p value
Age		303	1 [0.98–1.01]	0.88
Sex	Male vs. Female	303	0.86 [0.56–1.32]	0.49
Tumor site	Head and neck vs. Extremities	382	0 [0–Inf]	0.660
	Internal trunk vs. Extremities	382	0.77 [0.5–1.18]
	Superficial trunk vs. Extremities	382	0.81 [0.47–1.4]
Pathological type	Liposarcoma vs. Leiomyosarcoma	470	0.32 [0.19–0.53]	3.03E−06	458	1.07 [0.37–3.13]	0.901
	Myxofibrosarcoma vs. Leiomyosarcoma		0.45 [0.22–0.90]		458	0.56 [0.27–1.13]	0.104
	Undifferentiated sarcoma vs. Leiomyosarcoma		0.45 [0.30–0.67]		458	0.38 [0.12–1.22]	0.104
	Others vs. Leiomyosarcoma		0.22 [0.08–0.60]		458	0.57 [0.37–0.86]	7.89E−03
Depth	Superficial vs. Deep	128	0.6 [0.14–2.55]	0.49
Pathological grade	1 vs. 3	169	0 [0.00–Inf]	0.69
	2 vs. 3		1.25 [0.75–2.09]
Median pathological size		142	0.99 [0.94–1.05]	0.77
Pathological size	pT2 vs. pT1	142	1.69 [0.51–5.62]	0.39
Genetic profile	Complex vs. Simple	458	2.28 [1.37–3.79]	1.59E−03	458	2.52 [0.82–7.75]	0.108
CINSARC class	Poor vs. Good	470	2.52 [1.79–3.57]	1.59E−07	458	1.99 [1.38–2.87]	2.25E−04
PDL1 class	High vs. Low	470	1.9 [1.35–2.68]	2.35E−04	458	1.51 [1.06–2.16]	2.37E−02

Figure 2. Correlations of PDL1 expression with immune features in soft-tissue sarcomas. (A) Metagene expression scores in all STS (N = 758) reported as a box plot according to PDL1 expression status for T cells and CD8⁺ T-cells metagenes and two prognostic immune kinase gene expression signature (LCK and immune kinases). (B) Similar to (A), but showing the probability of activation of immune pathways including IFNα, IFNγ, and TNFα pathways. The p-values (Student's t-test) are indicated.